Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Semin Arthritis Rheum. 2018 Mar 28;48(3):513–522. doi: 10.1016/j.semarthrit.2018.03.016

Figure 3.

Figure 3

Kaplan-Meier analysis plots showing time to discontinuation of each medication. The Y axis shows the proportion of patients who were still receiving each medication at any point in time. The X axis shows the months from initial treatment.

A, Intravenous methylprednisolone (IVMP). The median time to discontinuation of IVMP was 5 months from the initiation of IVMP treatment in patients diagnosed before 1997 vs. 25 months in patients diagnosed after 1997.

B, Methotrexate. The median time to discontinuation of methotrexate was 46 months from methotrexate treatment initiation in patients diagnosed before 1997 vs. 81 months in patients diagnosed after 1997.

C, Intravenous immunoglobulin (IVIG). The median time to discontinuation of IVIG was 13 months after IVIG treatment initiation in patients diagnosed before 1997 vs. 53 months in patients diagnosed after 1997.

D, Antimalarial drugs. The median time to discontinuation of antimalarial drugs was 37 months after initiation of antimalarial drugs in patients diagnosed before 1997 vs. 39 months in patients diagnosed after 1997.